Azura Ophthalmics - Taking a unique approach to the treatment of ocular surface disease
Employees: 11-50
Total raised: $40M
Founded date: 2014
Investors 1
| Date | Name | Website |
| - | OrbiMed | orbimed.co... |
Funding Rounds 2
| Date | Series | Amount | Investors |
| 26.10.2020 | - | $20M | - |
| 10.10.2017 | Series B | $20M | - |
Mentions in press and media 7
| Date | Title | Description |
| 02.04.2024 | Azura Ophthalmics to Present New Data Supporting the Potential of AZR-MD-001 to be the First Ophthalmic Keratolytic for Ocular Surface Diseases | —Azura to present 10 abstracts at the American Society of Cataract and Refractive Surgery (ASCRS) and the Association for Research in Vision and Ophthalmology (ARVO), showcasing a breadth of data supporting the potential for a new therapeut... |
| 07.09.2021 | Azura Ophthalmics Appoints Biopharma Industry Veteran Steven Altschuler, M.D. as Chair of the Board | Azura Ophthalmics Ltd., a clinical-stage company developing innovative therapies for Meibomian Gland Dysfunction (MGD) and related eye diseases, today announced the appointment of Steven M. Altschuler, M.D., as chair of its board of directo... |
| 26.10.2020 | Azura Ophthalmics Raises US$20M in Funding | Azura Ophthalmics Ltd., a Tel Aviv, Israel-based clinical-stage company developing innovative therapies for Meibomian gland dysfunction (MGD) and related eye diseases, raised US$20m in funding. The round was led by a syndicate of existing i... |
| 23.10.2020 | Azura Ophthalmics raises AUD$28m for registration studies for treatment of leading cause of dry eye disease | Azura Ophthalmics Ltd., a clinical-stage company developing innovative therapies for Meibomian gland dysfunction (MGD) and related eye diseases, today announced a AUD$28m raise. The round included participation from existing investors, incl... |
| 19.10.2017 | Biotech startup Azura Ophthalmics raises $20 million to cure dry eye disease | Azura Ophthalmics chief Marc Gleeson. Source: Supplied. Australian and Israeli-based biotech startup Azura Ophthalmics has raised $US16 million ($20 million) to fund treatments for a disease many in the startup world may not be aware of, bu... |
| 10.10.2017 | OrbiMed Leads $16M Series B for Azura Ophthalmics | TEL AVIV, Israel--(BUSINESS WIRE)--Azura Ophthalmics Ltd. (Azura), a clinical-stage biotechnology company developing innovative therapies for meibomian gland dysfunction (MGD), today announced it has completed a $16 million Series B funding... |
| 10.10.2017 | Azura Ophthalmics Receives $16M in Series B Funding | Azura Ophthalmics Ltd., a Tel Aviv-Yafo, Israel-based clinical-stage biotechnology company developing innovative therapies for meibomian gland dysfunction (MGD), completed a $16m Series B funding. The round was led by a syndicate of OrbiMed... |